Rhode Island 2026 Regular Session

Rhode Island House Bill H7075

Introduced
1/14/26  

Caption

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

Impact

The bill seeks to enhance the health and safety of individuals with diabetes by making critical treatment options more accessible. By eliminating copayments and deductibles for glucagon, it addresses a significant barrier that often prevents timely administration of this life-saving medication. Additionally, it provides clarity on health plan responsibilities regarding coverage, thus establishing a more supportive framework for diabetes management within the community.

Summary

House Bill 7075, known as the Matthew Federico Diabetic Safety Act, mandates that all health insurance contracts providing prescription coverage in Rhode Island must include at least one type of glucagon auto-injector or nasal spray without requiring a copayment or deductible. This provision aims to improve access to essential diabetes treatment by ensuring that individuals experiencing hypoglycemia can obtain the necessary medical intervention without financial barriers. The requirement will take effect on January 1, 2027, allowing time for insurance companies to adapt their policies accordingly.

Contention

While proponents of the bill argue that it will save lives by increasing access to glucagon during emergencies, there are concerns about the financial implications for health insurers and the potential for increased premium costs. Critics may point to the need for careful monitoring of the market impacts following the implementation of this requirement, raising questions about long-term sustainability and affordability in the state’s health insurance landscape. Nonetheless, the bill has garnered support from various sugar advocacy groups and diabetes organizations advocating for improved health outcomes.

Companion Bills

No companion bills found.

Previously Filed As

RI H5173

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

RI S0115

Requires health plans that provide prescription benefits to cover at least one type of glucagon auto-injector, nasal spray, or formulation that does not require reconstitution to treat hypoglycemia. No copayment or deductible would be required.

RI H6422

Requires every individual or group health insurance contract, plan, or policy to provide coverage for at least one type of buprenorphine for each form of administration.

RI H5486

Requires certified athletic trainers to be trained in the administration of epinephrine auto-injectors (epi-pens) and would require such professionals to be equipped with the medication while performing professional activities.

RI S0321

Requires certified athletic trainers to be trained in the administration of epinephrine auto-injectors (epi-pens) and would require such professionals to be equipped with the medication while performing professional activities.

RI H5302

Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.

RI S0461

Caps the total amount that a covered person is required to pay for a covered prescription inhaler, prescription device, or prescription equipment to twenty-five dollars ($25.00) per thirty (30) day supply.

RI S0168

Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.

RI H5120

Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.

RI S0053

Provides an insurer would not impose prior authorization requirements for any service ordered by an in-network primary care provider.

Similar Bills

FL H0597

Diabetes Management in Schools

NJ A4548

Concerns administration of ready-to-use undesignated glucagon rescue therapy in public schools.

KY HB75

AN ACT relating to undesignated glucagon.

KY HB174

AN ACT relating to undesignated glucagon.

FL S0772

Diabetes Management in Schools

KY HB263

AN ACT relating to undesignated glucagon.

MA H671

Relative to undesignated glucagon rescue therapies in schools

TX HB350

Relating to the use of glucagon medication on certain public and private school campuses.